WallStSmart
FULC

Fulcrum Therapeutics Inc

NASDAQ: FULC · HEALTHCARE · BIOTECHNOLOGY

$7.15
-3.90% today

Updated 2026-04-29

Market cap
$522.15M
P/E ratio
P/S ratio
2.66x
EPS (TTM)
$-1.18
Dividend yield
52W range
$4 – $16
Volume
1.2M

Fulcrum Therapeutics Inc (FULC) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item201720182019202020212022202320242025
Revenue$0.00$0.00$750000.00$8.82M$19.16M$6.34M$2.81M$80.00M$0.00
Revenue growth (YoY)+1076.4%+117.2%-66.9%-55.8%+2752.0%-100.0%
Cost of revenue$715000.00$1.34M$2.05M$2.38M$2.52M$76.78M$71.80M$63.39M$1.39M
Gross profit$-715000.00$-1.34M$-2.05M$8.82M$19.16M$-70.44M$2.81M$16.61M$-1.39M
Gross margin-273.7%100.0%100.0%-1110.7%100.0%20.8%
R&D$18.49M$25.18M$71.07M$59.04M$69.70M$76.78M$71.80M$63.39M$56.10M
SG&A$4.50M$8.31M$13.14M$21.39M$30.52M$41.69M$41.67M$34.97M$28.67M
Operating income$-22.99M$-33.50M$-84.22M$-71.61M$-81.05M$-112.56M$-110.66M$-21.90M$-84.77M
Operating margin-11228.9%-811.6%-423.0%-1774.9%-3945.2%-27.4%
EBITDA$-22.28M$-32.15M$-82.16M$-69.23M$-78.54M$-109.72M$-108.49M$-18.24M$-73.49M
EBITDA margin-10955.2%-784.7%-409.8%-1730.1%-3867.8%-22.8%
EBIT$-22.99M$-33.50M$-84.22M$-71.61M$-81.05M$-112.13M$-110.66M$-19.83M$-74.88M
Interest expense$0.00$0.00$0.00$0.00$2.72M$2.69M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-22.96M$-32.59M$-79.11M$-68.44M$-78.33M$-109.87M$-97.33M$-9.72M$-74.88M
Net income growth (YoY)-41.9%-142.8%+13.5%-14.5%-40.3%+11.4%+90.0%-670.0%
Profit margin-10548.4%-775.7%-408.8%-1732.4%-3470.1%-12.2%